Business
BriaCell’s Positive Clinical And Quality Of Life Data In Advanced Metastatic Breast Cancer Could Provide Hope For Patients
By Ernest Dela Aglanu, Benzinga --News Direct--Small and big pharma companies such as Pfizer Inc. (NYSE: PFE), Celldex Therapeutics Inc. (NASDAQ: CLDX), and
About this update from Celldex Therapeutics, Inc.
[{"type":"text","content":"By Ernest Dela Aglanu, Benzinga\n--News Direct--Small and big pharma companies such as Pfizer Inc. (NYSE: PFE), Celldex Therapeutics Inc. (NASDAQ: CLDX), and Hologic Inc. (NASDAQ: HOLX) are ramping up efforts to help reduce or eliminate the growing breast cancer mortality rate.As it stands now, breast cancer is the second most common cause of cancer death in women in the U.S. It is estimated that 43,780 people — 43,250 women and 530 men — will die from breast cancer this year alone.Globally, female breast cancer is the fifth leading cause of death. An estimated 684,996 women worldwide died from breast cancer in 2020, with metastatic breast cancer causing the vast majority of the deaths.The increasing death rate has led companies like BriaCell Therapeutics Corp. (NASDAQ: BCTX) (NASDAQ: BCTXW) (TSX: BCT) to advance research and development into therapies that could prove more effective against breast and other cancers.Focusing initially on breast cancer, BriaCell is dedicated to enhancing the lives of people with cancer with limited therapy options by developing novel immunotherapies to fight the disease.Immunotherapies have become the forefront of cancer treatments because they use the body’s immune system to destroy cancer cells, offer the potential for higher levels of safety and efficacy than chemotherapy and may also prevent cancer recurrence.BriaCell currently has a non-exclusive clinical trial collaboration with Incyte Corporation (NASDAQ: INCY) to evaluate the effects of combinations of novel clinical candidates.BriaCell is currently conducting a Phase I/II clinical trial of its lead product candidate, Bria-IMT™, in combination with the immunotherapy development candidate retifanlimab, an anti-PD-1 antibody provided by Incyte, for the treatment of advanced breast cancer.Positive Clinical And Quality Of Life DataOn December 8, BriaCell presented positive safety/tolerability and efficacy data from its lead product candidate – Bria-IMT™ – summarized in three poster sessions during the 2022 San Antonio Breast Cancer Symposium ® (SABCS).Summary Of The Positive DataPositive clinical data reported includes tumor shrinkage, disease control, progression-free survival, and potential long-term survival benefit in advanced metastatic breast cancer patients treated with the Bria-IMT™ combination regimen.“Better quality of life” and “le...